TRCT
CYTO

Tower Research Capital (TRC)’s Altamira Therapeutics Ltd CYTO Stock Holding History

Tower Research Capital (TRC)’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,660
Closed -$3.44K – 6192
2024
Q1 		$3.44K Buy
1,660
+809
+95% +$1.72K ﹤0.01% 4866
2023
Q4 		$2.96K Buy
+851
New +$3.7K ﹤0.01% 5145
2022
Q3 		– Sell
-57
Closed -$11K – 6707
2022
Q2 		$11K Buy
+57
New +$18.4K ﹤0.01% 4408
2022
Q1 		– Sell
-17
Closed -$8.21K – 6807
2021
Q4 		$12K Buy
17
+15
+750% +$10.1K ﹤0.01% 4355
2021
Q3 		$2K Buy
+2
New +$2.25K ﹤0.01% 5338
2021
Q2 		– Sell
-14
Closed -$19K – 6001
2021
Q1 		$19K Buy
+14
New +$18.8K ﹤0.01% 3940
2020
Q4 		– Sell
-1
Closed – – 5485
2020
Q3 		$0 Buy
+1
New +$376 ﹤0.01% 5189
2016
Q2 		– Hold
0
– -$1K – 5133
2016
Q1 		– Hold
0
– – – 3843
2015
Q4 		– Hold
0
– -$31K – 5207
2015
Q3 		– Hold
0
– – – 1375
2015
Q2 		– Hold
0
– -$14K – 5185
2015
Q1 		– Hold
0
– – – 2546
2014
Q4 		– Hold
0
– – – 2266
2014
Q3 		– Hold
0
– – – 2604

Other funds holding CYTO

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

Tower Research Capital (TRC)'s CYTO Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2024, closing a stake of 1,660 shares — an estimated $3.44K sold.

Tower Research Capital (TRC) first reported a position in CYTO in Q3 2020 and held it in 7 quarters. The position peaked at $19K in Q1 2021. 4 funds tracked by Wall St. Rank hold CYTO as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Altamira Therapeutics Ltd position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,660 Altamira Therapeutics Ltd shares in Q2 2024, an estimated $3.44K.
  • Tower Research Capital (TRC) first reported a position in Altamira Therapeutics Ltd in Q3 2020 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Altamira Therapeutics Ltd position peaked at $19K in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.